Complementary Medicines Australia Ltd.
Complementary Medicines Australia Ltd.
04/16/2026 | Press release | Distributed by Public on 04/15/2026 21:39
Andrographis paniculata (Andrographis) and anaphylaxis – updated safety review and supplementary report
Andrographis paniculata (Andrographis) and anaphylaxis - updated safety review and supplementary report
The TGA has released a targeted consultation on a proposal to remove Andrographis paniculata (Andrographis) from the Permissible Ingredients Determination. The proposal, made under high-moderate risk changes to the Permissible Ingredients Determination, is based on an updated TGA safety review following continued reports received by the TGA of anaphylaxis and/or hypersensitivity reactions to medicines containing Andrographis. The TGA has invited stakeholders, including consumer associations, health professionals, medicine sponsors and industry peak bodies, including CMA, to provide feedback on the proposed removal of Andrographis from the permitted ingredients list.
The consultation closes Thursday 30 April.
Complementary Medicines Australia Ltd. published this content on April 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 16, 2026 at 03:39 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]